This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder

Sponsored by Michele Staton

About this trial

Last updated 3 years ago

Study ID

R34DA045856-01

Status

Completed

Type

Interventional

Phase

Early Phase 1

Placebo

No

Accepting

18+ Years
All Sexes

Trial Timing

Ended 4 years ago

What is this trial about?

The overall aim of this R34 proposal is to examine the feasibility, acceptability, and short-term outcomes associated with an innovative service delivery model to increase adherence to extended-release naltrexone (XR-NTX) during the transition from jail to the community for rural individuals with opioid use disorder (OUD). The significance of this study is grounded in the public health emergency associated with the opioid epidemic in rural Appalachia, the increased vulnerability of rural individuals with OUD, and the dearth of available and accessible evidence-based treatment in the region. This study has potential to make a significant contribution to the OUD treatment field by advancing knowledge on innovative service delivery models to increase access to evidence-based treatment to reduce the prevalence of opioid use disorders and related health disparities among hard-to-reach, high-risk, underserved populations.

What are the participation requirements?

Inclusion Criteria

* Meets criteria for opioid use disorder

* Anticipated release date within 30 days

* Opioid free

* Not currently in methadone or buprenorphine trial

* No serious medical or psychiatric condition

* Willingness to enroll in the trial

Exclusion Criteria

* Positive study pregnancy test

* Abnormal liver function tests (5X upper limits of normal)

* Chronic pain conditions that require opioid therapies

* Untreated medical or psychiatric disorder

* Suicidal ideation

* BMI > 40